Trial · NCT05041322

Improving Ventilatory Capacity in Those With Chronic High Level SCI

NCT05041322, Phase 2, Completed, Spaulding Rehabilitation Hospital; results first posted 2025-09-18

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Improving Ventilatory Capacity in Those With Chronic High Level SCI. Trials, record NCT05041322. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05041322

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Improving Ventilatory Capacity in Those With Chronic High Level SCI
NCT number: NCT05041322
Status: Completed
Phases: Phase 2
Enrollment: 13 participants, actual
Lead sponsor: Spaulding Rehabilitation Hospital
Conditions: Spinal Cord Injuries
Interventions: Buspirone, Placebo
First posted: 2021-09-13
Last updated: 2025-09-18
Results first posted: 2025-09-18
Limitations and caveats: Insufficient sample size to make any determination of efficacy.

Source ClinicalTrials.gov

Registered outcomes4

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Pulmonary Function	14 Days	Forced expiratory volume over 1 second (FEV1).
Primary	Hypercapnic Ventilatory Response	14 Days	A change in the drive to breathe with a change in carbon dioxide
Primary	Sleep Quality	14 Days	Sleep apneas and hypopneas per hour.
Primary	Exercise Pulmonary Capacity	14 Days	Change in peak oxygen consumption during exercise

Source ClinicalTrials.gov

Outcomes4

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Pulmonary Function	14 Days	L	MEAN
PRIMARY	Hypercapnic Ventilatory Response	14 Days	L /min/mmHg of CO2	MEAN
PRIMARY	Sleep Quality	14 Days	counts per hour	MEAN
PRIMARY	Exercise Pulmonary Capacity	14 Days	ml/kg of O2	MEAN

Source ClinicalTrials.gov

Results by group8

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Pulmonary Function	Placebo	3.59	Standard Deviation 1.07	L
Pulmonary Function	Buspirone	3.77	Standard Deviation 1.12	L
Hypercapnic Ventilatory Response	Placebo	0.659	Standard Deviation 0.320	L /min/mmHg of CO2
Hypercapnic Ventilatory Response	Buspirone	0.566	Standard Deviation 0.133	L /min/mmHg of CO2
Sleep Quality	Placebo	4.26	Standard Deviation 2.11	counts per hour
Sleep Quality	Buspirone	6.18	Standard Deviation 2.97	counts per hour
Exercise Pulmonary Capacity	Placebo	18.28	Standard Deviation 8.20	ml/kg of O2
Exercise Pulmonary Capacity	Buspirone	17.69	Standard Deviation 7.29	ml/kg of O2

Source ClinicalTrials.gov

Participant flow18

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Baseline	STARTED	Placebo Then Buspirone	5
Baseline	STARTED	Buspirone Then Placebo	4
Baseline	COMPLETED	Placebo Then Buspirone	4
Baseline	COMPLETED	Buspirone Then Placebo	4
Baseline	NOT COMPLETED	Placebo Then Buspirone	1
Baseline	NOT COMPLETED	Buspirone Then Placebo	0
Treatment 1 (14 Days)	STARTED	Placebo Then Buspirone	4
Treatment 1 (14 Days)	STARTED	Buspirone Then Placebo	4
Treatment 1 (14 Days)	COMPLETED	Placebo Then Buspirone	2
Treatment 1 (14 Days)	COMPLETED	Buspirone Then Placebo	3

1 to 10 of 18Source ClinicalTrials.gov

See all 18 participant flow

Adverse events2

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Gastrointestinal distress	Gastrointestinal disorders	Buspirone	0	5
other	Gastrointestinal distress	Gastrointestinal disorders	Placebo	1	6

Source ClinicalTrials.gov

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Buspirone	0	5
Total, all-cause mortality	Placebo	0	6
Total, other adverse events	Buspirone	0	5
Total, other adverse events	Placebo	1	6
Total, serious adverse events	Buspirone	0	5
Total, serious adverse events	Placebo	0	6

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Buspirone vs Placebo: deaths from any cause	Trial comparisons
Buspirone vs Placebo: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT05041322

GET https://conductscience.org/api/trials/v1/NCT05041322/registered

API reference For AI assistants